Supplement Combination on Stress and Sleep

Last updated: July 1, 2025
Sponsor: University of South Carolina
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

N/A

Treatment

AM and PM Placebo

PM Active Supplement Combination (Magnesium threonate, L-theanine, and apigenin)

All Active Supplement Combinations (Ashwagandha, Rhodiola rosea, magnesium threonate, L-theanine, and apigenin))

Clinical Study ID

NCT06889584
Pro00141237
  • Ages 18-50
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of this clinical trial is to assess the effects of a supplement combination on measures of sleep quality and stress in healthy adults.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Healthy participants aged 18 to 50 years (inclusive) at the time of screening with abody mass index of 18.5 to 29.9 kg/m2.

  • Willing to give voluntary consent, be able to understand and read thequestionnaires, carry out all study-related procedures, communicate effectively withthe study staff, and agree to allow any study-related evaluations.

  • Participant is physically active: participating in resistance and/or enduranceexercise ≥150 min/wk for ≥6 mo.

  • Participant will be asked about dietary supplementation use within the past 6months.

If participant began taking a supplement within the past month, participant will be asked to discontinue supplement use followed by a 2-week washout prior to participation.In all other cases, supplement use will be asked to be maintained throughout the study.

• The participant has an apple device with iOS 16 or greater software.

Exclusion

Exclusion Criteria:

  • Have a known sensitivity of allergy to any of the investigational products.

  • Participants currently taking any of the investigational products will be excluded.

  • Female participants who are lactating, pregnant, or planning to become pregnantduring the study.

  • Diagnosed with any sleep-related or stress-related disorders.

  • Currently taking medication to manage sleep or cortisol levels.

  • Participants with controlled or uncontrolled hypertension including stage 1hypertension (systolic blood pressure ≥129 mmHg and diastolic blood pressure ≥89mmHg).

  • Any other condition or abnormality that, in the opinion of the investigator, wouldcompromise the safety of the participant or the quality of the study data.

Study Design

Total Participants: 115
Treatment Group(s): 4
Primary Treatment: AM and PM Placebo
Phase:
Study Start date:
February 15, 2025
Estimated Completion Date:
August 01, 2025

Connect with a study center

  • University of South Carolina Sport Science Lab

    Columbia, South Carolina 29208
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.